Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Merck's Vioxx will continue to chase Pfizer's Celebrex, but that it will never catch up. According to a new Pharmacor report entitled Osteoarthritis, Pfizer's COX-2 inhibitor franchise will dominate the osteoarthritis market, reaching $1.6 billion in 2011.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"Pfizer will follow up the success of Celebrex with its second-generation COX-2 inhibitor, Bextra. While Pfizer puts its marketing machine to work on Bextra, Merck will lose ground on its second-generation COX-2 inhibitor, Arcoxia, because of a late 2004 FDA approval," said Bornadata Evans Bain, Ph.D., analyst at Decision Resources. "Although Arcoxia/Vioxx sales will total a respectable $1.14 billion in 2011, the franchise will still significantly trail that of Celebrex/Bextra."

Disease Background-Osteoarthritis

Osteoarthritis is a noninflammatory degenerative joint disease. It is the most common form of arthritis and one of the most frequent causes of physical disability in adults. In 2001, the number of prevalent cases of OA in the seven major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) totaled 298 million. However, owing to a lack of technologies for early diagnosis of OA, only a fraction of these people were actually diagnosed with the disease. During the next five to ten years, diagnosis rates for OA will increase as a result of a greater awareness of the disease made possible by access to resources on the Internet and by extensive direct-to-consumer advertising in the United States.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Osteoarthritis is an Immune and Inflammatory Disorders report.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.decisionresources.com/.

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X46348694

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Over-the-Counter Claritin has the Potential to Significantly Reduce The Nonsedating Antihistamine Prescription Market

View Now